Back to search
FDAFDA · Food and drugs·Recall number D-1084-2014

Levothyroxine Sodium Tablets, USP, 200 mcg, 100-count bottle, Rx only, Distributed by Mylan Pharmaceuticals Inc. Morgantown, WV 26505, NDC 0378-1819-01

Published February 19, 2014 · Recall initiated: January 14, 2014

Summary

FDA records drug Class II recall D-1084-2014, published February 19, 2014 and initiated January 14, 2014. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 138,970 bottles; Lot: Lot 3037531 EXP 03/14 Lot 3038284 EXP 04/14. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: Assay results obtained during stability testing for Levothyroxine Sodium Tablets, USP were below specification.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Nationwide.
Lot
Lot 3037531 EXP 03/14 Lot 3038284 EXP 04/14
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levothyroxine Sodium Tablets, USP, 200 mcg, 100-count bottle, Rx only, Distributed by Mylan Pharmaceuticals Inc. Morgantown, WV 26505, NDC 0378-1819-01 recalled?

Yes. FDA published recall D-1084-2014 on February 19, 2014. Reported hazard: Subpotent Drug: Assay results obtained during stability testing for Levothyroxine Sodium Tablets, USP were below specification.

What should I do if I have this product?

Voluntary: Firm initiated · Letter